Latest Conference Articles

January 4th 2016, 3:00pm

Genitourinary Cancers Symposium (ASCO GU)

Cabozantinib significantly improved progression-free survival versus everolimus in patients with renal cell carcinoma regardless of the degree of metastases, type or number of prior treatments, or patient risk status.

December 14th 2015, 4:15pm

San Antonio Breast Cancer Symposium

Palbociclib enhances cell cycle control when added to anastrazole in the neoadjuvant setting in women with ER-positive primary breast cancer.

December 12th 2015, 10:04am

San Antonio Breast Cancer Symposium

The PD-1 inhibitor pembrolizumab had an overall response rate of 12% in PD-L1–positive patients with ER-positive/HER2-negative advanced breast cancer.

December 12th 2015, 8:25am

San Antonio Breast Cancer Symposium

The oral pan-HER TKI neratinib continued to show similar rates of disease-free survival for patients with HER2-positive early-stage breast cancer at a 3-year analysis of the phase III ExteNET trial.

December 11th 2015, 2:23pm

San Antonio Breast Cancer Symposium

Patricia Ganz, MD, UCLA Jonsson Comprehensive Cancer Center, discusses a study comparing anastrozole versus tamoxifen in patients with ductal carcinoma in situ (DCIS) breast cancer.

December 11th 2015, 1:30pm

San Antonio Breast Cancer Symposium

Breast cancer recurrence was similar whether postmenopausal women with ductal carcinoma in situ received anastrozole or tamoxifen for 5 years following local excision in the IBIS-II trial.

December 11th 2015, 1:18pm

San Antonio Breast Cancer Symposium

Patient reports of their experiences with taking either tamoxifen or anastrozole can help clinicians decide which one to recommend to individual women, new research has found.

December 11th 2015, 11:47am

San Antonio Breast Cancer Symposium

Joanne Blum, MD, PhD, oncologist with Texas Oncology and a member of the Breast Cancer Committee for The US Oncology Network, discuses the EMBRACA trial.

December 11th 2015, 10:35am

San Antonio Breast Cancer Symposium

T-DM1 (ado-trastuzumab emtansine; Kadcyla) reduced the risk of death by 32% and improved median overall surviva by almost 7 months compared with physician's choice of therapy in heavily pretreated patients with HER2-positive advanced breast cancer.

December 11th 2015, 9:09am

San Antonio Breast Cancer Symposium

Treatment with the PI3K inhibitor buparlisib plus fulvestrant showed a 1.9-month extension in progression-free survival compared with fulvestrant alone in women with endocrine-resistant HR-positive/HER2-negative advanced breast cancer.

December 11th 2015, 6:09am

San Antonio Breast Cancer Symposium

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute United Kingdom, discusses a study evaluating the safety and clinical activity of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (TNBC).

December 11th 2015, 6:08am

San Antonio Breast Cancer Symposium

The enzyme APOBEC3B has been associated with resistance to treatment with tamoxifen in retrospective studies and xenograft models of ER-positive breast cancer.

December 11th 2015, 6:04am

San Antonio Breast Cancer Symposium

Estrogen receptor mutations are prevalent and associated with poorer survival in patients with pretreated HR+/HER2- metastatic breast cancer.

December 10th 2015, 5:14pm

San Antonio Breast Cancer Symposium

Achieving a pCR with standard neoadjuvant chemotherapy plus carboplatin and/or bevacizumab was associated with a survival improvement in patients with triple-negative breast cancer.

December 10th 2015, 2:46pm

San Antonio Breast Cancer Symposium

The risk of complications from mastectomy plus reconstruction was increased by two-fold compared with lumpectomy plus whole breast irradiation, after adjustment for other treatment differences.

December 10th 2015, 1:22pm

San Antonio Breast Cancer Symposium

Women who opt for breast-conserving therapy and radiation to treat their early-stage breast cancer are about 20% more likely to be alive after 10 years compared with their counterparts who had mastectomy.

December 10th 2015, 12:59pm

San Antonio Breast Cancer Symposium

Reuben S. Harris, PhD, investigator Howard Hughes Medical Institute and professor in the Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota College of Biological Sciences, explains the role APOBEC3B may play in tamoxifen resistance in ER-positive breast cancer.

December 10th 2015, 12:20pm

San Antonio Breast Cancer Symposium

Frontline treatment with the PD-L1 inhibitor atezolizumab combined with nab-paclitaxel showed a confirmed objective response rate of 66.7% in patients with metastatic triple-negative breast cancer.

December 10th 2015, 12:13pm

San Antonio Breast Cancer Symposium

Adding carboplatin to neoadjuvant chemotherapy improves disease-free survival significantly in women with triple-negative breast cancer but not HER2-positive breast cancer.

December 10th 2015, 7:06am

San Antonio Breast Cancer Symposium

Pat Whitworth, MD, medical oncologist at the Nashville Breast Center, discusses the prospective neo-adjuvant NBRST study, which looked at BluePrint functional subtyping versus conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast tumors.